{"transactions":[{"id":847187,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2026-03-12T16:05:07.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":136612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":658037,"source":{"system":"sec-edgar","filing":"0001193125-26-104111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000119312526104111/ownership.xml","form_type":"4"}},{"id":882699,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Common Stock","published_at":"2026-02-25T16:05:17.000Z","date":"2026-02-24","kind":"sale","planned":false,"acquired":true,"shares":17012,"price":3.66,"value":62263.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":521425,"source":{"system":"sec-edgar","filing":"0001193125-26-071503","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000119312526071503/ownership.xml","form_type":"4"}},{"id":882698,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2026-02-25T16:05:17.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":15570,"price":3.81,"value":59321.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $4.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":538437,"source":{"system":"sec-edgar","filing":"0001193125-26-071503","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000119312526071503/ownership.xml","form_type":"4"}},{"id":1272458,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2025-02-12T21:00:08.000Z","date":"2025-02-10","kind":"sale","planned":false,"acquired":false,"shares":41269,"price":1.76,"value":72633.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":554007,"source":{"system":"sec-edgar","filing":"0000950170-25-019235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017025019235/ownership.xml","form_type":"4"}},{"id":1272457,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2025-02-12T21:00:08.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":133333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":595276,"source":{"system":"sec-edgar","filing":"0000950170-25-019235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017025019235/ownership.xml","form_type":"4"}},{"id":1298229,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2025-01-22T17:04:41.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":48224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted March 2, 2022. The earned PSUs were certified and vested on January 17, 2025."}],"balance_after":461943,"source":{"system":"sec-edgar","filing":"0000950170-25-007852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017025007852/ownership.xml","form_type":"4"}},{"id":1506160,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2024-05-22T16:05:12.000Z","date":"2024-05-20","kind":"sale","planned":false,"acquired":false,"shares":16128,"price":6.45,"value":104025.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":413719,"source":{"system":"sec-edgar","filing":"0000950170-24-063481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024063481/ownership.xml","form_type":"4"}},{"id":1582345,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Performance-based Restricted Stock Unit","published_at":"2024-03-12T16:05:16.000Z","date":"2024-03-08","kind":"exercise","planned":false,"acquired":false,"shares":34936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each PSU represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs are earned upon the Issuer's Class A Common Stock achieving a specified price per share."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Additional PSUs may vest upon the Issuer's Class A Common Stock achieving specified prices per share beyond the previously achieved vesting targets."}],"balance_after":0,"derivative":{"expiration_date":"2026-02-28","underlying":"Class A Common Stock","underlying_shares":34936},"source":{"system":"sec-edgar","filing":"0000950170-24-029906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024029906/ownership.xml","form_type":"4"}},{"id":1582344,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2024-03-12T16:05:16.000Z","date":"2024-03-08","kind":"exercise","planned":false,"acquired":true,"shares":34936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted on March 8, 2023. The earned PSUs were certified on February 12, 2024, and March 7, 2024, and vested on March 8, 2024."}],"balance_after":429847,"source":{"system":"sec-edgar","filing":"0000950170-24-029906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024029906/ownership.xml","form_type":"4"}},{"id":1644122,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Performance-based Restricted Stock Unit","published_at":"2024-02-14T20:53:45.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":27214,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share."}],"balance_after":27214,"derivative":{"expiration_date":"2027-02-28","underlying":"Class A Common Stock","underlying_shares":27214},"source":{"system":"sec-edgar","filing":"0000950170-24-015557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024015557/ownership.xml","form_type":"4"}},{"id":1644121,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2024-02-14T20:53:45.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":54427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":394911,"source":{"system":"sec-edgar","filing":"0000950170-24-015557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024015557/ownership.xml","form_type":"4"}},{"id":1644120,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2024-02-14T20:53:45.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":38618,"price":15.24,"value":588538.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units and performance-based restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":340484,"source":{"system":"sec-edgar","filing":"0000950170-24-015557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000095017024015557/ownership.xml","form_type":"4"}},{"id":1675800,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2024-01-19T16:05:23.000Z","date":"2024-01-17","kind":"grant","planned":false,"acquired":true,"shares":57971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted March 26, 2021. The earned PSUs were certified and vested on January 17, 2024."}],"balance_after":379102,"source":{"system":"sec-edgar","filing":"0001209191-24-001905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919124001905/doc4.xml","form_type":"4"}},{"id":1880318,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-05-24T16:05:43.000Z","date":"2023-05-22","kind":"sale","planned":false,"acquired":false,"shares":10324,"price":10.12,"value":104478.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":321131,"source":{"system":"sec-edgar","filing":"0001209191-23-031874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123031874/doc4.xml","form_type":"4"}},{"id":1959601,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Performance-based Restricted Stock Units","published_at":"2023-03-10T17:13:57.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":34935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share."}],"balance_after":34935,"derivative":{"expiration_date":"2026-02-28","underlying":"Class A Common Stock","underlying_shares":34935},"source":{"system":"sec-edgar","filing":"0001209191-23-017889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123017889/doc4.xml","form_type":"4"}},{"id":1959600,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-03-10T17:13:57.000Z","date":"2023-03-08","kind":"grant","acquired":true,"shares":69869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":331455,"source":{"system":"sec-edgar","filing":"0001209191-23-017889","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123017889/doc4.xml","form_type":"4"}},{"id":1984893,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-03-01T18:21:08.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":2416,"price":11.31,"value":27324.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020 and April 24, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":261586,"source":{"system":"sec-edgar","filing":"0001209191-23-014280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123014280/doc4.xml","form_type":"4"}},{"id":1984892,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-03-01T18:21:08.000Z","date":"2023-02-28","kind":"sale","acquired":false,"shares":7438,"price":11.31,"value":84123.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":264002,"source":{"system":"sec-edgar","filing":"0001209191-23-014280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123014280/doc4.xml","form_type":"4"}},{"id":1984891,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-03-01T18:21:08.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":2322,"price":11.41,"value":26494.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020 and April 24, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":271440,"source":{"system":"sec-edgar","filing":"0001209191-23-014280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123014280/doc4.xml","form_type":"4"}},{"id":1984890,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-03-01T18:21:08.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":7146,"price":11.41,"value":81535.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":273762,"source":{"system":"sec-edgar","filing":"0001209191-23-014280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123014280/doc4.xml","form_type":"4"}},{"id":2051544,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2023-01-19T16:05:59.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":14663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs) granted February 27, 2020 and April 24, 2020. The earned PSUs were certified and vested on January 17, 2023."}],"balance_after":280908,"source":{"system":"sec-edgar","filing":"0001209191-23-003999","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919123003999/doc4.xml","form_type":"4"}},{"id":2257299,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-05-25T16:05:16.000Z","date":"2022-05-23","kind":"sale","acquired":false,"shares":7453,"price":11.5,"value":85709.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 50% of the reporting person's restricted stock units granted on March 26, 2021."}],"balance_after":266245,"source":{"system":"sec-edgar","filing":"0001209191-22-031842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122031842/doc4.xml","form_type":"4"}},{"id":2257298,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-05-25T16:05:16.000Z","date":"2022-05-23","kind":"sale","acquired":false,"shares":3130,"price":11.5,"value":35995.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on April 24, 2020."}],"balance_after":273698,"source":{"system":"sec-edgar","filing":"0001209191-22-031842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122031842/doc4.xml","form_type":"4"}},{"id":2351484,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-04T16:05:31.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":81448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":276828,"source":{"system":"sec-edgar","filing":"0001209191-22-016184","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122016184/doc4.xml","form_type":"4"}},{"id":2362590,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-02T16:01:08.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":4364,"price":10.77,"value":47000.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021."}],"balance_after":195380,"source":{"system":"sec-edgar","filing":"0001209191-22-014652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122014652/doc4.xml","form_type":"4"}},{"id":2362589,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-02T16:01:08.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":3804,"price":10.77,"value":40969.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on April 24, 2020"}],"balance_after":199744,"source":{"system":"sec-edgar","filing":"0001209191-22-014652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122014652/doc4.xml","form_type":"4"}},{"id":2362588,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-02T16:01:08.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":5161,"price":10.77,"value":55583.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020."}],"balance_after":203548,"source":{"system":"sec-edgar","filing":"0001209191-22-014652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122014652/doc4.xml","form_type":"4"}},{"id":2362587,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-02T16:01:08.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":2911,"price":10.77,"value":31351.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020."}],"balance_after":208709,"source":{"system":"sec-edgar","filing":"0001209191-22-014652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122014652/doc4.xml","form_type":"4"}},{"id":2362586,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-03-02T16:01:08.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":1367,"price":10.77,"value":14722.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2019."}],"balance_after":211620,"source":{"system":"sec-edgar","filing":"0001209191-22-014652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919122014652/doc4.xml","form_type":"4"}},{"id":2429167,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2022-01-21T17:56:19.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":29326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares earned upon satisfaction of certain performance criteria associated with performance-based restricted stock units (PSUs)\ngranted February 27, 2020 and April 24, 2020. The earned PSUs were certified and vested on January 19, 2022."}],"balance_after":212987,"source":{"system":"sec-edgar","filing":"0001104659-22-006551","document":"tm224209-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000110465922006551/tm224209-3_4seq1.xml","form_type":"4"}},{"id":2496488,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO,SVP,Head-Res&Drug"}}],"security":"Class A Common Stock","published_at":"2021-11-24T16:08:18.000Z","date":"2021-11-23","kind":"sale","acquired":false,"shares":13776,"price":11.58,"value":159526.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 100% of the reporting person's restricted stock units granted on December 16, 2019."}],"balance_after":183661,"source":{"system":"sec-edgar","filing":"0001209191-21-066780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121066780/doc4.xml","form_type":"4"}},{"id":2696054,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2021-05-26T16:05:27.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":2077,"price":12.25,"value":25443.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on April 24, 2020."}],"balance_after":197437,"source":{"system":"sec-edgar","filing":"0001209191-21-035905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121035905/doc4.xml","form_type":"4"}},{"id":2768693,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2021-03-30T17:09:56.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":38655,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units, granted as a retention award, vest as to 50% of the shares of Class A Common Stock on each of May 19, 2022 and May 18, 2023."}],"balance_after":199514,"source":{"system":"sec-edgar","filing":"0001209191-21-023576","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121023576/doc4.xml","form_type":"4"}},{"id":2822779,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2021-03-02T16:44:58.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":3041,"price":9.11,"value":27703.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020."}],"balance_after":160859,"source":{"system":"sec-edgar","filing":"0001209191-21-016108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121016108/doc4.xml","form_type":"4"}},{"id":2822778,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2021-03-02T16:44:58.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":1398,"price":9.11,"value":12735.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2019."}],"balance_after":163900,"source":{"system":"sec-edgar","filing":"0001209191-21-016108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121016108/doc4.xml","form_type":"4"}},{"id":2836975,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2021-02-24T16:17:52.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":58252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":165298,"source":{"system":"sec-edgar","filing":"0001209191-21-013772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919121013772/doc4.xml","form_type":"4"}},{"id":3168595,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":61367,"kind":"person","name":"Shetzline Michael","position":1,"cik":"0001808509","reported_name":"Shetzline Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO, SVP & Head of Drug Devt."}}],"security":"Class A Common Stock","published_at":"2020-04-28T16:03:37.000Z","date":"2020-04-24","kind":"grant","acquired":true,"shares":20740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock units, granted as a recognition award, vest as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":107046,"source":{"system":"sec-edgar","filing":"0001209191-20-025918","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808509/000120919120025918/doc4.xml","form_type":"4"}}]}